Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Floats 15-Month Review Timeline For PDUFA V; Firms Mull Tradeoff On Speed Vs. Certainty

Executive Summary

Fifteen months could become the expected review time for new molecular entity and novel biologics license applications, based on a proposed new review model.
Advertisement

Related Content

FDA Wants To Lengthen Review Time For Some Prior Approval Supplements
PDUFA V: FDA Relaxes Pre-Submission Meeting Requirement
FDA May Require NDA Pre-Filing Meeting Under PDUFA V Review Model; Pilot Launching Soon
PDUFA V: FDA Application Completeness Crackdown Continues
What’s A "Complete" Application? Clarity From FDA Could Speed Review Times
Transparency Phase III: FDA Offers Designs For Industry Review
Out Of The Shadow Of REMS: FDA Review Documents Show Emerging Importance Of Post-Marketing Requirements
FDA May Be Catching Up With FDAAA Workload, Latest Performance Data Suggests
PDUFA Update: FDA Wants To Automatically Extend Complex Application Reviews
PDUFA Update: FDA Wants To Automatically Extend Complex Application Reviews

Topics

Advertisement
UsernamePublicRestriction

Register

PS052925

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel